Melinda Poyer, DO
Family Medicine · Rock Springs, WYNPI 1033175831
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in WY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 128 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$489
- Lilly USA, LLC$321
- Lundbeck LLC$312
- Novo Nordisk$185
- Amarin Pharma, Inc.$169
- Amgen$140
- plus $647 from 17 others
What the payments were for
- Food & beverage$2,25199%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 18 | $489 |
| Lilly USA, LLC | 20 | $321 |
| Lundbeck LLC | 17 | $312 |
| Novo Nordisk | 12 | $185 |
| Amarin Pharma, Inc. | 14 | $169 |
| Amgen | 8 | $140 |
| Merck | 9 | $131 |
| GSK | 5 | $84 |
| Vanda Pharmaceuticals Inc. | 2 | $58 |
| Pfizer | 4 | $57 |
| Sunovion Pharmaceuticals Inc. | 2 | $43 |
| AstraZeneca | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 3 | $42 |
| Johnson & Johnson | 2 | $35 |
| Hologic Sales And Service, LLC | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Biogen | 1 | $17 |
| Bayer | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$2,262 in reported general payments places this provider in the 90th percentile of 237 family medicine providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 150 | $146,532 |
| OzempicSemaglutide | 99 | $100,022 |
| MounjaroTirzepatide | 61 | $67,368 |
| JanuviaSitagliptin Phosphate | 47 | $58,837 |
| RexultiBrexpiprazole | 21 | $30,597 |
| JardianceEmpagliflozin | 24 | $28,558 |
| XareltoRivaroxaban | 23 | $28,440 |
| FarxigaDapagliflozin Propanediol | 22 | $23,281 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $22,969 |
| TradjentaLinagliptin | 14 | $16,947 |
| TrulicityDulaglutide | 11 | $14,792 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $14,234 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $12,105 |
| VascepaIcosapent Ethyl | 22 | $11,290 |
| LinzessLinaclotide | 15 | $9,238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Prempro | $57 | $149,383162 claims |
| Novo NordiskOzempic | $185 | $100,02299 claims |
| Lilly USA, LLCMounjaro, Trulicity | $321 | $82,16172 claims |
| MerckJanuvia | $131 | $58,83747 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $42 | $30,59721 claims |
| Johnson & JohnsonXarelto | $35 | $28,44023 claims |
| AstraZenecaFarxiga, Symbicort | $43 | $26,48333 claims |
| GSKBreo Ellipta | $84 | $22,96946 claims |
| AbbVieLinzess, Synthroid | $489 | $10,91063 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 237 family medicine providers in Wyoming.
Other family medicine in Rock Springs
- Jacob JohnsonRock Springs$5K
- Lawrence LauridsenRock Springs$4K
- Brytton LongRock Springs$3K
- David DansieRock Springs$1K
- Michael BowersRock Springs$1K
- Joseph SchoeberCasper$176K
- James McLennanCasper$13K
- Karlynn SieversCasper$10K
- Eric LawrenceCasper$7K
- Jonathon MedinaCheyenne$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.